Organogenesis Holdings Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Organogenesis Holdings Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $81 of operating cash. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$81Over the last 3 years, every $100 of reported profit came with $81 of operating cash.
Lower than 90% of Healthcare companies in United States.
Self-Funding Ratio
0.7×Over the last 3 years its own operating cash paid for 72% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 67% of Healthcare companies in United States.
Cash Locked Ratio
$38For every $100 of sales, $38 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $18 tied up three years earlier.
More money tied up than 79% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$19Sales grew 25% in 3 years; of every extra $100 of sales, $19 became extra profit.
Higher than 50% of Healthcare companies in United States.
Asset Productivity Ratio
+25% / +33%In 3 years sales changed by +25% while total assets changed by +33%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 68% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Lower than 51% of Healthcare companies in United States.
Tangible Assets Ratio
94%Of every $100 the company owns, $94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 68% of Healthcare companies in United States.
Tangible Net Worth Ratio
91%Of every $100 of net worth, $91 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 73% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Organogenesis Holdings Inc. made a loss over the last year. Organogenesis Holdings Inc. owes $0.29 for every $1 it owns. Net profit rose 4201% in the year to Dec 2025, and grew 34% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOrganogenesis Holdings Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.46The share price is 0.46 times Organogenesis Holdings Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$133 MThe total market value of all of Organogenesis Holdings Inc.'s shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$288 MWhat Organogenesis Holdings Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.24Net worth divided by the number of shares. The share price of $1.03 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-25.9%Organogenesis Holdings Inc. lost 25.9% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
Owes vs Owns
0.29×Organogenesis Holdings Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Dividend yield
NoneOrganogenesis Holdings Inc. does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Profit growth
+4201%Net profit rose 4201% in the year to Dec 2025, and grew 34% a year on average over 3 years.
Profit margin
6.6%Organogenesis Holdings Inc. keeps $7 of every $100 of revenue as net profit.
Cash quality
-0.3×Cash from Organogenesis Holdings Inc.'s business was -0.3× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Cash vs debt
Net cashOrganogenesis Holdings Inc. held $12 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Organogenesis Holdings Inc.: $133 M ÷ $288 M (30 Jun 2026) = 0.5.
What is Organogenesis Holdings Inc.'s return on equity?
Organogenesis Holdings Inc. lost 25.9% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
How much does Organogenesis Holdings Inc. owe compared with what it owns?
Organogenesis Holdings Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Does Organogenesis Holdings Inc. pay a dividend?
No. Organogenesis Holdings Inc. does not currently pay a dividend.
Is Organogenesis Holdings Inc.'s revenue growing?
Revenue rose 17% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.